The intra-aortic balloon pump (IABP) is the most widely used of all circulatory assist devices today (1) . The IABP was first employed 30 years ago as a treatment of last resort for a mortally ill patient suffering from cardiogenic shock (2, 3) . Today, this treatment modality is routinely used in a wide range of serious cardiovascular conditions, ranging from hemodynamic stabilization in patients suffering from complications of acute myocardial infarction (AMI) or cardiogenic shock, to very high risk patients undergoing angioplasty or coronary artery bypass grafting (CABG) (4 -6) .
As potential clinical applications of counterpulsation continue to expand, there is an increasing need to prospectively document the current clinical experience with IABP. No study has extensively documented the indications, clinical outcomes, patient hemodynamics, concomitant medications, complications, risk factors and insertion techniques associated with IABP. Therefore, a comprehensive, prospective, multicenter computerized database program was developed: the Benchmark Counterpulsation Outcomes Registry. The present report summarizes the development and implementation of the registry, and reviews cumulative data compiled from 17,540 IABP records from 16, 909 patients between the initiation of data collection in June 1996 and August 2000.
METHODS
The Benchmark Counterpulsation Outcomes Registry was started in June 1996, initially included 22 contributing clinical centers, and presently includes 243 institutions in 18 countries. An independent steering committee (Appendix A) designed and implemented the investigator-initiated registry. Datascope Corp. (Fairfield, New Jersey) provided funding for the database, and the sites included in the registry were institutions that used intra-aortic balloons (IABs) manufactured by Datascope Corp. Patient popula-tions included all patients in participating institutions who received IABP between June 1996 (or time of institution enrollment) and August 2000. Concomitant medications and procedures were left to the discretion of the treating physician. Figure 1 outlines data handling within the registry. Participating sites were provided with a computer for entering data on all consecutive IABP cases. Database software (Lotus Notes platform) was custom-written so investigators could easily enter clinical data relating to indications of IABP, details of the balloon insertion, patient hemodynamics, concomitant medications, complications and in-hospital outcomes. Site data were forwarded via modem to a single registry storage location and handled on a central file server. Continuous updates, individual site data and registry information were available on-line at the participating sites. More complex data queries were performed by request at the central storage facility. Statistics. Descriptive summaries included frequency and percent distributions for the categorical variables, and the sample mean, standard deviation, minimum, median and maximum for the quantitative assessments. Logistic regression methodology was used to study effects of demographic, medical history and preprocedure factors on the occurrence of a major IABP complication. A full model containing all selected factors was first obtained, then a reduced model was generated containing only those factors that individually tested as statistically significant (p Յ 0.05) within the model. The reduced model also had to fit as well as the full model as measured by the reduction in the likelihood ratio chi-square statistic. All analyses were performed using SAS, version 8, using the Windows 98 operating system from an IBM-compatible PC. End points. We collected data on four primary end points: ischemia, bleeding, IABP failure and in-hospital mortality. Major limb ischemia was defined as a loss of pulse or sensation, or abnormal limb temperature or pallor, requiring surgical intervention. Minor ischemia was defined as decreased arterial flow as manifested by diminished pulse that resolves with balloon removal, and not resulting in any impairment of body function.
An association with hemodynamic compromise, required blood transfusion or surgical intervention defined severe bleeding. Nonsevere bleeding involved minor hematomas and oozing from puncture site, and did not require blood transfusion or surgical intervention. The IAB failure was defined as poor augmentation, inability to deploy or any IAB leak suggested by blood inside the catheter tubing, gas loss or catheter alarm. All-cause hospital mortality was defined as mortality occurring from any cause during IABP or after IABP. Mortality directly related to IABP was also tabulated. A secondary endpoint was major IAB-related complications, defined as any major limb ischemia, severe bleed, IAB leak or mortality directly attributed to IABP. Registry validation. In order to maximize the reliability of the registry from which these data were gathered, an external audit (data validation) of the Benchmark Registry was undertaken (StatTrade, Inc., Morrisville, Pennsylvania) that was sponsored by Datascope. Randomly selected database case histories from 21 hospitals with 2,339 patient records were audited and compared to actual local site records. The audit involved 485 (20.7%) records entered in 1999. Seventy items were checked from each record, resulting in an audit of 33,950 entries. Check-box items had at least a 95% accuracy (lower 95% confidence bound), and dates had at least a 90% accuracy. In addition, virtually all IABP cases were being reported by each participating hospital.
RESULTS

Clinical variables and indications.
Between June 1996 and September 2000, 16,909 individual IABP patients were enrolled in the database. Of the enrolled patients, 68.8% were male, 31.2% were female and the mean age was 65.9 years (Table 1) . From the perspective of clinical history, 25.6% of patients had diabetes, 11.9% had peripheral vascular disease (PVD), 30.6% had experienced a prior myocardial infarction and 14.6% had undergone prior CABG surgery. In 15.4% of patients, the presenting symp-
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AMI ϭ acute myocardial infarction BSA ϭ body surface area CABG ϭ coronary artery bypass graft IAB ϭ intra-aortic balloon IABP ϭ intra-aortic balloon pump LOS ϭ length of stay PVD ϭ peripheral vascular disease Figure 1 . Data handling in the Benchmark Registry. Data from consecutive patients are collected at participating centers, entered into a computer on-site and subsequently transferred to a central storage facility. Individual site and overall registry data are available to the participants, as well as customized queries of the database.
toms involved the left main coronary artery, while 28.5% had triple-vessel disease. Some of the patients only underwent diagnostic catheterization procedures (9.3%) or percutaneous coronary intervention procedures (23.0%); the majority of procedures were surgical (60.7%; 89.4% of the surgical patients were undergoing CABG). Of the total 16,909 patients, 13,020 (77%) underwent cardiac catheterization and 4,833 (28.6%) underwent percutaneous coronary intervention. Of the 9,179 patients undergoing CABG surgery, 1,672 (18.2%) underwent CABG alone, 6,655 (72.5%) underwent diagnostic catheterization and CABG, and 852 (9.3%) underwent percutaneous coronary intervention and CABG.
The most frequent indication for use of IABP was to provide hemodynamic support during or after cardiac catheterization (20.6% of patients) ( Table 2 ). Other common clinical indications included cardiogenic shock (18.8%), weaning from cardiopulmonary bypass (16.1%), refractory unstable angina (12.3%) and preoperative use in high risk patients (13.0%). Balloon insertion. Balloon insertions were performed in the catheterization laboratory or procedure room (63.0%), the operating room (24.0%), the intensive care unit (4.0%), the emergency department (0.2%) and other locations (8.8%). Patients received either 40 ml (77.3%), 34 ml (21.5%) or other size balloons (1.2%). Insertion technique involved a sheath in 79.7% of patients, and employed a 9.5F (78.4%) or an 8F catheter (21.6%; 8F devices have been available since June 1, 1997). The insertion was accomplished percutaneously in 95.4% of cases. The approach was right femoral (63.3%), left femoral (35.6%) or an alternate approach (1.1%). The mean duration of IABP in the overall registry cohort was 53 h (median ϭ 41 h, most frequent time ϭ 24 h, range from 5 min to 89 days). In-hospital balloon-related complications. The incidence of balloon-related complications in the overall registry cohort was low (Table 3) . Major complications of balloon counterpulsation were defined as severe bleeding, major limb ischemia, balloon leak or in-hospital mortality related to IABP. A total of 2.6% of all patients experienced at least one major complication.
Limb ischemia (defined as reduced arterial flow as manifested by diminished pulse) occurred in 2.9% of cases, but major limb ischemia (loss of pulse, loss of sensation, abnormal limb temperature or pallor requiring surgical intervention, arterial repair or amputation) was reported in only 0.9% of patients. Balloon leak occurred in 1.0% of cases. The incidence of severe bleeding (bleeding at the balloon insertion site leading to hemodynamic compromise and requiring a transfusion or surgical intervention) was 0.8%. Of the balloon insertions, 2.6% were unsuccessful due to a balloon leak, poor inflation of a balloon, poor augmentation or difficulties associated with balloon insertion (Table  4 ). The incidence of in-hospital mortality related to IABP was 0.05%. Not surprisingly, overall in-hospital mortality in this seriously ill population was high (21.2%, 11.6% with the IAB in place). The mean length of stay (LOS) in this cohort was 14 days (median ϭ 10 days, most frequent LOS ϭ 7 days, range from 1 day to 384 days). Multivariate logistic regression analysis was used to identify significant independent predictors of a major complication of IABP, including death related to IABP, major limb ischemia, severe bleeding or balloon leak. Of the 15 variables screened, only female gender, PVD, small body surface area (BSA) (Ͻ1.65 m 2 ) and higher age (Ն75 years) significantly increased the risk of a major complication. Table 5 identifies the risk factors in order by odds ratio.
DISCUSSION
The major finding of this study is that the incidence of major balloon-related complications is encouragingly low (2.8%). Advances such as percutaneous insertion and smaller-diameter catheters have considerably reduced the incidence of serious vascular complications (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . In addition, the incidence of unsuccessful IABP due to balloon leak, poor inflation, poor augmentation or insertion difficulty was extremely low (2.3%), and to our knowledge, no previous study has examined this issue. Complications and risk factors. The overall complication rates noted in this real-world observational experience compare favorably with other published observational experiences (Table 6 ) (24 -26). Both major limb ischemia (0.9%) and major bleeding (0.8%) are lower than in the previously reported experiences; this may be due to use of smaller catheters and advances in the use of heparin and glycoprotein inhibitors. Use of the IABP has been shown to reduce recurrent ischemia (24) and improve overall clinical outcomes (4) . In the present study, the actual number of deaths attributable to IABP failure or insertion is approximately 5 in 10,000, with a low incidence of other balloon-related complications, suggesting that IABP is a low risk therapeutic option in a high risk patient cohort. In fact, previous studies report low balloon-related mortality, and there seems to be less balloon-related mortality over time (Table  6 ) (27) .
Sheathless insertion techniques have not replaced the ) and age (Ն75 years) remain the four prominent, independent predictors of a serious IABP complication. These four high risk groups may become a focus of efforts to improve clinical outcomes and to reduce IABP complications. Indications. The American College of Cardiology/American Heart Association guideline indications for IABP use include preparation for angiography and revascularization in cardiogenic shock that has not quickly reversed, acute mitral regurgitation or ventricular septal defect, refractory post-MI angina, refractory ventricular arrhythmias with hemodynamic instability, hemodynamic instability, poor left ventricular function or recurrent ischemia (28) . However, no study other than this one has examined indications for IABP use. The data from this registry suggest that the most frequent indication for IABP was to provide hemodynamic support in the catheterization laboratory, and the most frequent site of IAB insertion was in the catheterization laboratory. Thus, IABP appears to have been embraced as an adjunctive technique in patients undergoing invasive cardiac procedures. The mean duration of hemodynamic support was 53 h, verifying the use of IABP for short-term hemodynamic support. The IABP was also widely used in patients with cardiogenic shock and in patients undergoing high risk surgical procedures. Interestingly, although CABG is considered a primary indication for IABP use, only 13% of patients received an IABP because they were undergoing a CABG procedure (Table 2 ). However, of the patients who received an IABP, more than half underwent CABG even if it was not the primary indication. Registry information. The National Registry of Myocardial Infarction is an ongoing, prospective registry that provides a framework for this registry (29) . The ongoing Benchmark Counterpulsation Outcomes Registry provides prospective data on all patients who receive IAB counterpulsation (IABP) support at over 243 hospitals in 18 countries. The database has considerable potential for examining current practice patterns, documenting outcome, and trending use and outcomes over time. For example, the impact of such advances as the recently released 8F balloon catheter system can be rigorously and prospectively evaluated through use of the IABC registry data. In addition, data from this registry will be used as a complement to standards based assessment (Appendix B). 
Study limitations.
The limitations of the present study are those inherent in any large-scale retrospective observational registry. This is not a randomized trial; rather, it is a detailed description of ongoing and evolutionary clinical practice. Most of the data were collected prospectively, however, some were collected based on review of patient charts and records. The data have not been 100% validated, but in contrast to other large-scale observational registries, the Benchmark registry has gone to considerable effort to validate the data. Finally, given the large number of participating clinical institutions, there are site-to-site variations in personnel and resources allocated to the registry, individual practice patterns and patient populations.
Retrospective analyses of risk factors should be regarded with caution because there is not necessarily a cause and effect relationship with the risk factors associated with major complications. However, the data strongly suggest the need for greater care and clinical attention in treating patients who are small, female, have PVD or who are at least 75 years of age, in view of their increased risk for experiencing a major complication of IABP. Summary. In this analysis if 16,909 patients enrolled form June 1996 to August 2000, the incidence of major complications was relatively low (2.8%) as were incidences of unsuccessful IABP (2.3%). In addition, the most frequent indication for use of IABP was for hemodynamic support in the catheterization laboratory, while use of IABP during CABG procedures remained relatively low. Female gender, small BSA, high age and PVD were independent predictors of a serious complication of IABP.
